Patents by Inventor Wan Namkung

Wan Namkung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Composition comprising punicalagin for inhibiting PAR2 activity
    Patent number: 11957699
    Abstract: The present invention relates to a composition for inhibiting PAR2 activity including punicalagin, and more specifically, the present invention provides a composition for inhibiting PAR2 activity including punicalagin, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, health functional food composition, or cosmetic composition for preventing or treating an inflammatory disease or pruritis.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: April 16, 2024
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Wan Namkung, Sang Won Lee, Yo Han Seo, Chin Hee Mun
  • NOVEL COMPOUND AND METHOD FOR PREVENTING OR TREATING OF RESPIRATORY DISEASES COMPRISING THE SAME AS AN ACTIVE INGREDIENT
    Publication number: 20220193041
    Abstract: The present invention relates to a novel compound, and a composition for preventing or treating of respiratory disease comprising the novel compound, E- or Z-isomer thereof, optical isomer thereof, a mixture of two isomers thereof, precursor thereof, pharmaceutically acceptable salt thereof or solvate thereof as an active ingredient.
    Type: Application
    Filed: April 1, 2020
    Publication date: June 23, 2022
    Inventors: Jae Young CHOI, Gyoonhee HAN, Wan NAMKUNG, Sung Ha PARK, Moo Suk PARK
  • Pharmaceutical composition for ANO1 antagonist with anticancer activity
    Patent number: 11274074
    Abstract: The present disclosure relates to a novel anticancer pharmaceutical composition. The present disclosure achieves an anticancer effect using a compound effective in inhibiting the expression of ANO1 (TMEM16A). In addition, the present disclosure provides an ANO1 (TMEM16A) antagonist using the compound inhibiting the expression of ANO1 (TMEM16A).
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: March 15, 2022
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION YONSEI UNIVERSITY
    Inventors: Wan Namkung, Ik Yon Kim, Yohan Seo, Jin Hwang Kim
  • COMPOSITION COMPRISING PUNICALAGIN FOR INHIBITING PAR2 ACTIVITY
    Publication number: 20210308165
    Abstract: The present invention relates to a composition for inhibiting PAR2 activity including punicalagin, and more specifically, the present invention provides a composition for inhibiting PAR2 activity including punicalagin, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, health functional food composition, or cosmetic composition for preventing or treating an inflammatory disease or pruritis.
    Type: Application
    Filed: July 30, 2019
    Publication date: October 7, 2021
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Wan NAMKUNG, Sang Won LEE, Yo Han SEO, Chin Hee MUN
  • PHARMACEUTICAL COMPOSITION FOR ANO1 ANTAGONIST WITH ANTICANCER ACTIVITY
    Publication number: 20200087250
    Abstract: The present disclosure relates to a novel anticancer pharmaceutical composition. The present disclosure achieves an anticancer effect using a compound effective in inhibiting the expression of ANO1 (TMEM16A). In addition, the present disclosure provides an ANO1 (TMEM16A) antagonist using the compound inhibiting the expression of ANO1 (TMEM16A).
    Type: Application
    Filed: September 18, 2019
    Publication date: March 19, 2020
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Wan NAMKUNG, Ik Yon KIM, Yohan SEO, Jin Hwang KIM
  • Small molecule activators of calcium-activated chloride channels and methods of use
    Patent number: 9790218
    Abstract: Provided herein are small molecule activators of calcium-activated chloride channels. These small molecules may be used for treatment of diseases and disorders that are treatable by activating calcium-activated chloride channels, such as cystic fibrosis, disorders related to salivary gland dysfunction (for example, Sjogren's syndrome and dysfunction following radiation injury), dry eye syndrome, and intestinal hypomotility.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: October 17, 2017
    Assignee: The Regents of the University of California
    Inventors: Alan S. Verkman, Wan Namkung
  • INDOLIZINO[3,2-c]QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CYSTIC FIBROSIS CONTAINING THE SAME AS ACTIVE INGREDIENT
    Publication number: 20160108042
    Abstract: Provided are an indolizino[3,2-c]quinoline derivative, pharmaceutically acceptable salt thereof, and a method for preparing the same. The indolizino[3,2-c]quinoline derivative, pharmaceutically acceptable salt thereof may function as an agonist of cystic fibrosis conductance transmembrane regulator, and thus may be useful for an agent for preventing or treating diseases caused by degradation of activity of cystic fibrosis conductance transmembrane regulator and for a pharmaceutical composition for stimulating proliferation of stem cells.
    Type: Application
    Filed: October 15, 2015
    Publication date: April 21, 2016
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Ikyon KIM, Wan NAMKUNG, Jonghyuk SUNG
  • Indolizino[3,2-c]quinoline derivatives, pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for treatment of cystic fibrosis containing the same as active ingredient
    Patent number: 9296751
    Abstract: Provided are an indolizino[3,2-c]quinoline derivative, pharmaceutically acceptable salt thereof, and a method for preparing the same. The indolizino[3,2-c]quinoline derivative, pharmaceutically acceptable salt thereof may function as an agonist of cystic fibrosis conductance transmembrane regulator, and thus may be useful for an agent for preventing or treating diseases caused by degradation of activity of cystic fibrosis conductance transmembrane regulator and for a pharmaceutical composition for stimulating proliferation of stem cells.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: March 29, 2016
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Ikyon Kim, Wan Namkung, Jonghyuk Sung
  • SMALL MOLECULE ACTIVATORS OF CALCIUM-ACTIVATED CHLORIDE CHANNELS AND METHODS OF USE
    Publication number: 20140378510
    Abstract: Provided herein are small molecule activators of calcium-activated chloride channels. These small molecules may be used for treatment of diseases and disorders that are treatable by activating calcium-activated chloride channels, such as cystic fibrosis, disorders related to salivary gland dysfunction (for example, Sjogren's syndrome and dysfunction following radiation injury), dry eye syndrome, and intestinal hypomotility.
    Type: Application
    Filed: August 3, 2012
    Publication date: December 25, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Alan S. Verkman, Wan Namkung
  • METHODS OF TREATING DISEASES WITH PROANTHOCYANIDIN OLIGOMERS SUCH AS CROFELEMER
    Publication number: 20120202876
    Abstract: Disclosed herein are methods of treating diseases including gastrointestinal disorders, such as secretory diarrheas, with the proanthocyanidin oligomer, crofelemer. Also disclosed is the anti-secretory effect of crofelemer on Calcium-activated chloride channels (CaCC) and Cystic fibrosis transmembrane conductance regulator (CFTR).
    Type: Application
    Filed: October 5, 2010
    Publication date: August 9, 2012
    Applicants: NAPO PHARMACEUTICALS, INC., REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Alan S. Verkman, Pravin Chaturvedi, Lukmanee Tradtrantip, Wan Namkung